pharmaphorum

APRIL 19, 2021

The UK’s unique offering as a life sciences research hub helped convince US biotech Novavax to develop its COVID-19 jab there, according to the head of the country’s Vaccines Taskforce. . Last August the UK government finalised a deal with Novavax to purchase 60 million doses of the NVX-CoV2373 vaccine, which will also be manufactured in the country at a plant owned by FUJIFILM Diosynth Biotechnologies in Stockton-on-Tees.

Vaccines 141

Vaccines 141

Outsourcing Pharma

APRIL 19, 2021

One Healthâs FidoCure is using genomics and AI technology to develop precision oncological treatments, and the work is benefiting human cancer research.

112

112

Drug Patent Watch

APRIL 19, 2021

Annual Drug Patent Expirations for HETLIOZ Hetlioz is a drug marketed by Vanda Pharms Inc and is included in two NDAs. It is available from one supplier. There are fifteen…. The post New patent for Vanda Pharms drug HETLIOZ appeared first on DrugPatentWatch - Make Better Decisions.

98

98

Pharma Times

APRIL 19, 2021

JCVI advises pregnant women in the UK be offered COVID-19 vaccination at the same time as the rest of the population

Vaccines 112

Vaccines 112

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

APRIL 23, 2021

Two years ago the use of AI in pharma and healthcare looked to be quickly heading for what Gartner’s Hype Cycle model would term the Plateau of Productivity. After the COVID-powered digital transformations of both pharma and healthcare , there can be little doubt that artificial intelligence is already having a productive time across our sector. It could even be, as consultants GlobalData predicted back in January, this year’s most disruptive technology across the pharmaceutical industry, though

115

115

Pharma Marketing Network

APRIL 21, 2021

[link]. The Pharma Marketing Podcast is pleased to present this special guest episode from our friend and Editorial Advisory Board member Darshan Kulkarni, Sales and Marketing Oversight – April 21, 2021. Darshan Kulkarni and Marc Banjak, General Counsel at Dova Pharmaceuticals, discuss sales compliance in the life sciences. Sales and marketing representatives in the life science industry must comply with state and federal regulations.

90

90

Pharma Times

APRIL 22, 2021

Study will include approximately 1,000 people with obesity or overweight with comorbidities

125

125

pharmaphorum

APRIL 20, 2021

Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator. . The cost-effectiveness agency has said that anti-CD20 antibody Kesimpta (ofatumumab) can be prescribed via the NHS in England and Wales as a treatment for adults with RMS with active disease, as either a first-line therapy or after alternative drugs have been tried.

Hospitals 109

Hospitals Documentation 109

Outsourcing Pharma

APRIL 20, 2021

Artelo Biosciences is investigating the viability of its novel cannabinoid product as a solution to treat cancer-related anorexia in oncology patients.

91

91

NY Times

APRIL 22, 2021

A new study shows that a 20-year-old drug prevents scarring in mice. If it works on humans, it could change the lives of those with disfiguring wounds.

68

68

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Pharma Times

APRIL 23, 2021

Drug demonstrated a 25% relative risk reduction in the first occurrence of major adverse cardiovascular events in REDUCE-IT trial

98

98

pharmaphorum

APRIL 19, 2021

French genomic medicines firm SparingVision has agreed to buy GAMUT Therapeutics, a biotech specialising in gene therapies for inherited eye diseases such as retinitis pigmentosa (RP) that could compete against Roche/Spark’s Luxturna in a wider patient group. . GAMUT’s lead product, now SPVN20, is a novel, mutation-agnostic gene therapy, which aims at restoring the function of dormant cone cells in the retina.

104

104

Outsourcing Pharma

APRIL 20, 2021

ImmunoScape plans to use the investor funds to grow its Asia presence, expand into the US, and to further develop its Deep Immunomics platform technology.

71

71

Drug Patent Watch

APRIL 22, 2021

Annual Drug Patent Expirations for PROCYSBI Procysbi is a drug marketed by Horizon Pharma Usa and is included in two NDAs. There are sixteen patents protecting this drug. Drug patent…. The post New patent for Horizon Pharma drug PROCYSBI appeared first on DrugPatentWatch - Make Better Decisions.

59

59

Pharma Times

APRIL 20, 2021

Decision is based on results from the Phase II DESTINY-Breast01 trial

129

129

pharmaphorum

APRIL 23, 2021

Amarin’s Vazkepa cardiology drug has been backed by the UK’s drugs regulator, following approval in Europe at the end of March. . The Medicines and Healthcare products Regulatory Agency (MHRA) granted a marketing authorisation for Vazkepa (icosapent ethyl) as a treatment to reduce risk of cardiovascular events in high-risk patients. These are defined as patients who have elevated triglycerides and either established cardiovascular disease or diabetes and at least one additional cardiovascular ri

Diabetes 98

Diabetes 98

Outsourcing Pharma

APRIL 19, 2021

A leader from digital health solutions firm CitiusTech suggests use of fast healthcare interoperability resources is useful in the face of evolving tech.

59

59

NY Times

APRIL 20, 2021

The European Union’s drug regulator said that the Johnson and Johnson vaccine should carry a warning of potential risk for rare blood clots on the label, but did not recommend stopping the vaccine, saying the benefits of the vaccine outweighed the risks.

Labelling 53

Labelling Vaccines Immunity Immunization 53

Pharma Times

APRIL 23, 2021

Construction on Leiden, Netherlands site anticipated to begin later this year

123

123

pharmaphorum

APRIL 19, 2021

The EMA has started reviewing the emergency use application for GlaxoSmithKline and Vir Biotech’s COVID-19 antibody VIR-7831, which could become the fourth drug of its type cleared for early use in the EU. . The monoclonal antibody – also known as GSK4182136 – is being evaluated for the treatment of people with mild or moderate COVID-19 who are aged over 12 and don’t need oxygen supplementation, but are considered to be at risk of developing more severe symptoms.

Immunity 98

Immunity Immunization 98

Drug Patent Watch

APRIL 23, 2021

Annual Drug Patent Expirations for ZYDELIG Zydelig is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are thirteen…. The post New patent expiration for Gilead Sciences drug ZYDELIG appeared first on DrugPatentWatch - Make Better Decisions.

52

52

Drug Channels

APRIL 23, 2021

Today’s guest post comes from Erica Conroy, Vice President of Specialty at CoverMyMeds. Erica discusses four technology areas that the healthcare network can embrace to increase speed to therapy, affordability, and adherence. To learn more about CoverMyMeds’ technology solutions, download their new whitepaper: Helping Patients Access Specialty Therapies: Autoimmune Conditions. ( Free download ).

52

52

Pharma Times

APRIL 19, 2021

Five-year strategy will seek to transform key elements of organisation's approach to latest treatments

101

101

pharmaphorum

APRIL 20, 2021

SWM and Healthware Join Forces to Help Physicians Connect to Science & Learning. Salerno, Italy / London, UK | 20 April 2021 – Healthware Group , an integrated global digital health organization with a focus on strategic consulting, marketing communications, and healthcare innovation has announced its acquisition of London-based SWM (Streaming Well Motion) , a creative motion lab and consultancy focused on virtual hybrid experiences, content development, and medical education.

Communication 98

Communication 98

Drug Patent Watch

APRIL 23, 2021

Annual Drug Patent Expirations for AUVI-Q Auvi-q is a drug marketed by Kaleo Inc and is included in one NDA. It is available from two suppliers. There are twenty-nine patents…. The post New patent for Kaleo Inc drug AUVI-Q appeared first on DrugPatentWatch - Make Better Decisions.

52

52

Pharma in Brief

APRIL 20, 2021

On April 10, 2021, the Rules Committee of the Federal Court of Appeal and the Federal Court (the Rules Committee ) launched a consultation on amendments to the Federal Courts Rules (the Rules ) on proportionality, abuse of process, and Federal Court of Appeal motions. In the Regulatory Impact Analysis Statement ( RIAS ), the Committee has stated these amendments are necessary to “allow the Courts to strike a balance between the importance and the complexity of the case and the amounts involved”,

Documentation 52

Documentation 52

Pharma Times

APRIL 20, 2021

Pharma and diagnostic sectors respond to organisation’s latest guideline recommendations

98

98

pharmaphorum

APRIL 19, 2021

NICE has included proposals to speed up evaluations and focus on new technology such as digital health in a new strategy to provide faster access to new medical treatments and innovations. . The cost-effectiveness body has produced a new vision for the next five years, after reflecting on lessons learned during the COVID-19 pandemic. NICE said the pandemic showed the importance of swiftness and flexibility and embracing new forms of innovation in healthcare technology.

Documentation 75

Documentation 75

Drug Patent Watch

APRIL 23, 2021

Annual Drug Patent Expirations for EVZIO Evzio is a drug marketed by Kaleo Inc and is included in two NDAs. There are thirty-two patents protecting this drug. Drug patent litigation…. The post New patent for Kaleo Inc drug EVZIO appeared first on DrugPatentWatch - Make Better Decisions.

52

52

Pharma Marketing Network

APRIL 20, 2021

With more than 30 years in the field, Dr. Horning has been a constant advocate for evidence-based treatment, helping to establish standards of care for patients across all types of Hodgkin and non-Hodgkin lymphoma. She has garnered prolific status as a researcher, leader and educator recognized with a prestigious Stanford School of Medicine Excellence in Patient Care Award, among many other honors.

Medical Schools 52

Medical Schools 52

Pharma Times

APRIL 22, 2021

The 2021 Clinical Researcher of the Year – The Americas will be closing for entry on the 14th of May.

83

83

pharmaphorum

APRIL 22, 2021

Biosensor firm physIQ has licensed its technology to Johnson & Johnson’s Janssen pharma unit in a multi-year deal, to investigate use of wearable sensors in virtual clinical trials. Janssen will be able to scale up use of Chicago-based physIQ’s biosensors to support both R&D and commercial activities. The pharma company will use the technology known as accelerateIQ to collect data across its clinical studies through a variety of wearable biosensors. physIQ has a portfolio of FDA-cleared

70

70

Drug Patent Watch

APRIL 23, 2021

Annual Drug Patent Expirations for EVZIO+%28AUTOINJECTOR%29 Evzio (autoinjector) is a drug marketed by Kaleo Inc and is included in one NDA. It is available from two suppliers. There are thirty-one…. The post New patent for Kaleo Inc drug EVZIO (AUTOINJECTOR) appeared first on DrugPatentWatch - Make Better Decisions.

52

52

Outsourcing Pharma

APRIL 22, 2021

On May 5, the Innovations in Drug Delivery webinar will feature views on trends and technology from AstraZeneca, i20 Therapeutics, and top researchers.

56

56

Pharma Times

APRIL 21, 2021

First self-administered, targeted B-cell therapy licensed for adults with relapsing forms of MS

87

87